Madam Therapeutics has been awarded a grant from the Netherlands Antibiotic Development Platform (NADP)

Madam Therapeutics announced that it is one of the four companies in the Netherlands that have been awarded a novel grant from the Netherlands Antibiotic Development Platform (NADP).

An important objective of NADP is to increase the productivity of research and development for new antibiotics and alternatives. In order to promote the accelerated development of promising ‘leads’, NADP has developed a financing instrument specifically for this purpose: the so-called NADP Vouchers.

These vouchers can be used in various phases of the drug development process to gain advice and intensive supervision of research projects from independent consultants or contract research organisations that have specific knowledge and expertise pertinent to the pharmaceutical development process and clinical applications. The options vary from lead identification and optimisation, patent applications, and market analysis to pre-clinical drug development.

Applications were received from different types of organisations: 1 university, 2 university medical center, 1 university of applied sciences, and 4 SMEs. Following expert review, the NADP Board decided on awarding 8 out of 13 submitted applications. “Awarding 8 out of 13 vouchers forms a promising start for our goal to accelerate research and development of new antibiotics and alternatives”, says Cees de Joncheere, chair NADP Executive Board in a press release.

Madam Therapeutics will use the voucher to support the development of it’s lead molecule SAAP-148.